Trademark: 88393561
Word
INGENIA THERAPEUTICS
Status Date
Monday, December 19, 2022
Filing Date
Friday, April 19, 2019
Published for Opposition
Tuesday, September 17, 2019
Abandoned Date
Monday, December 19, 2022
5 Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Ocular pharmaceuticals
42 Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields
The mark consists of a design featuring a circle containing blood vessels and five circles representing cells. The left half of the circle is grey and the right half is red, and the details and background of the mark are presented in negative space that will appear in the color of the surface upon which it is placed. The red stylized term "INGENIA" is presented to the right of the design over the grey stylized wording "THERAPEUTICS".
The color(s) red, grey is/are claimed as a feature of the mark.
"THERAPEUTICS"
Dec 19, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Dec 19, 2022
Abandonment - No Use Statement Filed
May 13, 2022
Notice Of Approval Of Extension Request E-Mailed
May 12, 2022
Sou Extension 5 Granted
May 5, 2022
Sou Extension 5 Filed
May 12, 2022
Case Assigned To Intent To Use Paralegal
May 5, 2022
Sou Teas Extension Received
Nov 3, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 1, 2021
Sou Extension 4 Granted
Nov 1, 2021
Sou Extension 4 Filed
Nov 1, 2021
Sou Teas Extension Received
Apr 30, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 28, 2021
Sou Extension 3 Granted
Apr 28, 2021
Sou Extension 3 Filed
Apr 28, 2021
Sou Teas Extension Received
Nov 3, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 30, 2020
Sou Extension 2 Granted
Oct 30, 2020
Sou Extension 2 Filed
Oct 30, 2020
Sou Teas Extension Received
Mar 10, 2020
Notice Of Approval Of Extension Request E-Mailed
Mar 6, 2020
Sou Extension 1 Granted
Mar 6, 2020
Sou Extension 1 Filed
Mar 6, 2020
Sou Teas Extension Received
Nov 12, 2019
Noa E-Mailed - Sou Required From Applicant
Sep 17, 2019
Official Gazette Publication Confirmation E-Mailed
Sep 17, 2019
Published For Opposition
Aug 28, 2019
Notification Of Notice Of Publication E-Mailed
Aug 14, 2019
Approved For Pub - Principal Register
Aug 14, 2019
Examiner's Amendment Entered
Aug 14, 2019
Notification Of Examiners Amendment E-Mailed
Aug 14, 2019
Examiners Amendment E-Mailed
Aug 14, 2019
Examiners Amendment -Written
Aug 13, 2019
Teas/Email Correspondence Entered
Aug 13, 2019
Correspondence Received In Law Office
Aug 8, 2019
Assigned To Lie
Aug 1, 2019
Teas Response To Office Action Received
Jul 1, 2019
Notification Of Non-Final Action E-Mailed
Jul 1, 2019
Non-Final Action E-Mailed
Jul 1, 2019
Non-Final Action Written
Jun 28, 2019
Assigned To Examiner
May 7, 2019
Notice Of Design Search Code E-Mailed
May 6, 2019
New Application Office Supplied Data Entered
Apr 23, 2019
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
